Early mortality during initial treatment of tuberculosis in patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: An 8-year retrospective cohort study (2006-2013)

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Bigna, Jean Joel R ^a   Noubiap, Jean Jacques N ^a,b   Agbor, Ako A ^c   Plottel, Claudia S ^d   Billong, Serge Clotaire ^c,e   Ayong, André Patrick R ^f   Koulla Shiro, Sinata ^c,g  

^a Department of Epidemiology and Public Health Pasteur Center of Cameroon ^*  (Cameroon)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MINISTRY OF PUBLIC HEALTH   (Cameroon)

^f UNIVERSITY OF DOUALA   (Cameroon)

^g YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; HEMOGLOBIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; BODY WEIGHT; CAMEROON; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; EDUCATIONAL STATUS; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDEPENDENT LIVING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; TREATMENT DURATION; TUBERCULOSIS; URBAN AREA; HIV INFECTIONS; HOSPITAL; HOSPITAL MORTALITY; MIDDLE AGED;

ADULT; CAMEROON; COINFECTION; FEMALE; HIV INFECTIONS; HOSPITAL MORTALITY; HOSPITALS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS;

EID: 84941791864     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132394     Document Type: Article

References (37)

1. Martinson NA, Hoffmann CJ, Chaisson RE. Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. Proceedings of the American Thoracic Society. 2011; 8(3):288-93. Epub 2011/06/10. doi:10.1513/pats.201010-064WR PMID: 21653530; PubMed Central PMCID: PMCPMC3132787.
2. MacPherson P, Moshabela M, Martinson N, Pronyk P. Mortality and loss to follow-up among HAART initiators in rural South Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2009; 103(6):588-93. Epub 2008/11/18. doi:10.1016/j.trstmh.2008.10.001 PMID: 19012940.
3. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006; 20(8):1181-9. Epub 2006/05/13. doi:10.1097/01.aids.0000226959.87471.01 PMID: 16691070.
4. Brinkhof MW, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2007; 45(11):1518-21. Epub 2007/11/09. doi:10.1086/522986 PMID: 17990236; PubMed Central PMCID: PMCPMC3687541.
5. Cox JA, Lukande RL, Lucas S, Nelson AM, Van Marck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS reviews. 2010; 12(4):183-94. Epub 2010/12/24. PMID: 21179183.
6. World Health Organization. WHO African Region: Cameroon statistics summary (2002-present) World Health Organization; 2014 [cited 2014 Aug 17]. Available: http://apps.who.int/gho/data/node. country.country-CMR.
7. World Health Organization. Cameroon: Tuberculosis profile: World Health Organization; 2014 [cited 2014 Aug 18]. Available: https://extranet.who.int/sree/Reports?op=Replet&name=/WHO-HQ-Reports/G2/PROD/EXT/TBCountryProfile&ISO2=CM&outtype=html&LAN=FR.
8. Programme National de lutte contre la Tuberculose. Guide pour les personnels de santé Yaoundé, Cameroon: Ministry of Public Health of Cameroon; 2012 [cited 2014 July 03]. Available: http://www.pnlt.cm/index.php/documentation/rapports-d-activites/cat-view/4-guidetechnique?orderby=dmdatecounter&ascdesc=DESC.
9. World Health Organization. Global tuberculosis report 2013 Geneva, Switzerland: World Health Organization; 2013 [cited 2014 Jul 23]. Available: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656-eng.pdf.
10. World Health Organization. Treatment of Tuberculosis: guidelines for national programmes Geneva, Switzerland: World Health Organization; 2010 [cited Nov 15 2014]. Available: http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833-eng.pdf?ua=1&ua=1.
11. Zachariah R, Spielmann MP, Harries AD, Salaniponi FML. Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death. Trans Roy Soc Trop Med Hyg 2002; 96:291-4. PMID: 12174782.
12. Ismail I, Bulgiba A. Predictors of death during tuberculosis treatment in TB/HIV co-infected patients in Malaysia. PLoS One. 2013; 8(8):e73250. doi:10.1371/journal.pone.0073250 PMID: 23951346; PubMed Central PMCID: PMC3741191.
13. Shaweno D, Worku A. Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study. BMC research notes. 2012; 5:682. doi:10.1186/1756-0500-5-682 PMID: 23234241; PubMed Central PMCID: PMC3585495.
14. Sileshi B, Deyessa N, Girma B, Melese M, Suarez P. Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: a retrospective cohort study. BMC infectious diseases. 2013; 13(1):297. Epub 2013/07/03. doi:10.1186/1471-2334-13-297 PMID: 23815342; PubMed Central PMCID: PMCPMC3703293.
15. Feasey NA, Banada PP, Howson W, Sloan DJ, Mdolo A, Boehme C, et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. Journal of clinical microbiology. 2013; 51 (7):2311-6. Epub 2013/05/17. doi:10.1128/jcm.00330-13 PMID: 23678061; PubMed Central PMCID: PMCPMC3697654.
16. Zachariah R, Spielmann MP, Harries AD, Salaniponi FM. Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2002; 96(3):291-4. PMID: 12174782.
17. Jonnalagada S, Harries AD, Zachariah R, Satyanarayana S, Tetali S, Keshav Chander G, et al. The timing of death in patients with tuberculosis who die during anti-tuberculosis treatment in Andhra Pradesh, South India. BMC public health. 2011; 11:921. Epub 2011/12/15. doi:10.1186/1471-2458-11-921 PMID: 22166132; PubMed Central PMCID: PMCPMC3254139.
18. Agbor AA, Bigna JJ, Billong SC, Tejiokem MC, Ekali GL, Plottel CS, et al. Factors Associated with Death during Tuberculosis Treatment of Patients Co-Infected with HIV at the Yaounde Central Hospital, Cameroon: An 8-Year Hospital-Based Retrospective Cohort Study (2006-2013). PLoS One. 2014; 9 (12):e115211. Epub 2014/12/17. doi:10.1371/journal.pone.0115211 PMID: 25506830.
19. Rubin D, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Statistics in medicine. 1991 Apr; 10(4):585-98. PubMed Central PMCID: PMC2057657. PMID: 2057657.
20. Little RJ, Rubin DB. Statistical Analysis With Missing Data: Wiley; 1987.
21. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Statistics in medicine. 2011; 30(4):377-99. Epub 2011/01/13. doi:10.1002/sim.4067 PMID: 21225900.
22. Deribe K, Yami A, Deribew A, Mesfin N, Colebunders R, Van Geertruyden JP, et al. Predictors of Mortality among Tuberculosis-HIV-Coinfected Persons in Southwest Ethiopia: A Case-Control Study. Journal of the International Association of Providers of AIDS Care. 2013. Epub 2013/08/24. doi:10.1177/2325957413500528PMID: 23966102; PubMed Central PMCID: PMCPMC3928041.
23. Mungrue K, Beharry A, Kalloo J, Mahabir S, Maraj T, Ramoutar R, et al. Trends in HIV/TB coinfection in Trinidad and Tobago for the period 1998-2007. J Int Assoc Physicians AIDS Care (Chic). 2009; 8 (3):170-5. Epub 2009/02/28. doi:10.1177/1545109709331471 PMID: 19246416.
24. Sharma SK, Soneja M. HIV & immune reconstitution inflammatory syndrome (IRIS). The Indian journal of medical research. 2011; 134(6):866-77. Epub 2012/02/09. doi:10.4103/0971-5916.92632 PMID: 22310819; PubMed Central PMCID: PMCPMC3284095.
25. Haddow LJ, Moosa MY, Mosam A, Moodley P, Parboosing R, Easterbrook PJ. Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa. PLoS One. 2012; 7(11):e40623. Epub 2012/11/16. doi:10.1371/journal.pone.0040623 PMID: 23152745; PubMed Central PMCID: PMCPMC3495974.
26. Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: The pitfalls of hasty or incomplete repairs. Immunological reviews. 2013; 254(1):343-54. Epub 2013/06/19. doi:10.1111/imr.12064 PMID: 23772630; PubMed Central PMCID: PMCPMC3694599.
27. Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, et al. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: Timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014; 65(4):423-8. Epub 2013/11/15. doi:10.1097/qai.0000000000000030 PMID: 24226057; PubMed Central PMCID: PMCPMC3943693.
28. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011; 365(16):1471-81. Epub 2011/10/21. doi:10.1056/NEJMoa1013911 PMID: 22010913.
29. Naidoo K, Baxter C, Abdool Karim SS. When to start antiretroviral therapy during tuberculosis treatment? Current opinion in infectious diseases. 2013; 26(1):35-42. Epub 2012/11/29. doi:10.1097/QCO.0b013e32835ba8f9 PMID: 23188213; PubMed Central PMCID: PMCPMC3616247.
30. Mfinanga SG, Kirenga BJ, Chanda DM, Mutayoba B, Mthiyane T, Yimer G, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. The Lancet infectious diseases. 2014; 14(7):563-71. Epub 2014/05/09. doi:10.1016/s1473-3099(14)70733-9 PMID: 24810491.
31. Assawasuwannakit P, Braund R, Duffull SB. A model-based meta-analysis of the influence of factors that impact adherence to medications. Journal of clinical pharmacy and therapeutics. 2014. Epub 2014/10/21. doi:10.1111/jcpt.12219PMID: 25328015.
32. Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, et al. Dosing frequency and medication adherence in chronic disease. Journal of managed care pharmacy: JMCP. 2012; 18(7):527-39. Epub 2012/09/14. PMID: 22971206.
33. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2000; 30 Suppl 2:S171-6. doi: 10.1086/313849 PMID: 10860902.
34. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. The American journal of managed care. 2009; 15(6):e22-e33. Epub 2009/06/12. PMID: 19514806.
35. Griffin JP. The Textbook of Pharmaceutical Medicine. 8 ed: Wiley; 2009. 776 p.
36. Heaney RP. Factors influencing the measurement of bioavailability, taking calcium as a model. The Journal of nutrition. 2001; 131(4Suppl):1344S-8S. Epub 2001/04/04. PMID: 11285351.
37. Pokrovskaya AV, Popova AA, Ladnaya NN, Yurin OG. [The duration of an HIV infection course and its influencing factors]. Terapevticheskii arkhiv. 2014; 86(11):20-3. Epub 2015/02/27. PMID: 25715482.